^
    Back
    Association details:
    Biomarker:MYD88 mutation
    Cancer:Diffuse Large B Cell Lymphoma
    Drug:Besponsa (inotuzumab ozogamicin) (DNA replication inhibitor, CD22-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2023
    Title:

    Efficacy and Safety of Zanubrutinib-Containing Regimens in Patients with Secondary CNS Relapse in Diffuse Large B-Cell Lymphoma

    Published date:
    11/02/2023
    Excerpt:
    Notably, MYD88, CD79B, or TP53 mutations tested at diagnosis in these patients were associated with significantly more favorable treatment response...
    DOI:
    https://doi.org/10.1182/blood-2023-181041